SML-8-73-1

SML-8-73-1 is a nucleotide-based KRASG12C inhibitor. SML-8-73-1 can be used for the study of non-small cell lung cancer (NSCLC) [1][2].

1536470-92-4

12352005

Ras

GPCR/G Protein; MAPK/ERK Pathway

Cancer

O=C1C(N=CN2[C@@H]3O[C@H](COP(OP(OCCNC(CCl)=O)(O)=O)(O)=O)[C@@H](O)[C@H]3O)=C2N=C(N)N1

C14H21ClN6O12P2

562.75

[1]Lim SM, et al. Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. Angew Chem Int Ed Engl. 2014 Jan 3;53 (1) :199-204.|[2]Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther. 2021 Nov 15;6 (1) :386.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-19315/

Reference compound1

No Development Reported

K-Ras